Abstract: A pharmaceutically efficacious pteridine compound of formula I: ##STR1## wherein A denote a bridging hydrocarbon group containing 1 to 8 carbon atoms and containing a ##STR2## group directly bonded to the phenyl group and one of the methylene radicals of the bridging A group is optionally replaced by --O--; R.sub.1 is hydrogen, a cycloalkyl group with up to 7 carbon ring atoms, or an alkyl group having 1 to 6 carbon atoms, benzyl, or aryl; R.sub.2 is hydrogen or an alkyl group having 1 to 6 carbon atoms, or wherein R.sub.1 and R.sub.2 together form a five- or six-membered heterocyclic group which optionally contains additional hetero atoms selected from the group consisting of nitrogen, oxygen, and sulfur; R.sub.3 is hydrogen or an alkyl group having 1 to 3 carbon atoms; R.sub.3 ' is hydrogen, an optionally substituted alkyl group having 1 to 3 carbon atoms, carboxyl, hydroxyl or R.sub.3 and R.sub.

Abstract: A pharmaceutically efficacious pteridine compound of formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, nitro, a --(A).sub.n --OR.sub.3 group, wherein R.sub.3 is hydrogen or a C.sub.1-6 alkyl group, a --(A).sub.n --NR.sub.4 R.sub.5 group, wherein R.sub.4 and R.sub.5 independently of each other are hydrogen or a C.sub.1-6 alkyl group or R.sub.4 and R.sub.5 together with the nitrogen atom form a 5- or 6-membered ring that is substituted with a C.sub.1-4 alkyl group and wherein A is a linking group having 1 to 6 linking carbon atoms, one of which can be replaced by oxygen and wherein n is zero or one, and wherein R.sub.2 is hydrogen or, independently of R.sub.1, has the same meaning as R.sub.1, with the proviso that R.sub.1 and R.sub.2 are not simultaneously hydrogen, and the physiologically acceptable acid addition salts thereof.